News
|
Webcast
Q4 2023 IRIDEX Earnings Conference Call
|
|
|||||||
Keyword Search
| Date | Title | Teaser | |
|---|---|---|---|
|
12/28/23
|
Summary ToggleIridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation | Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment MOUNTAIN VIEW, Calif. , Dec. 28, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for |
|
|
11/27/23
|
Summary ToggleIridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation | MOUNTAIN VIEW, Calif. , Nov. 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its successful |
|
|
11/14/23
|
Summary ToggleIridex Reports Third Quarter 2023 Financial Results and Business Update | MOUNTAIN VIEW, Calif. , Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results |
|
|
11/13/23
|
Summary ToggleIridex to Host Third Quarter Financial Results Conference Call on November 14, 2023 | The Company also announced plans to present at Stifel Healthcare Conference MOUNTAIN VIEW, Calif. , Nov. 13, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today |
|
|
10/26/23
|
Summary ToggleIridex to Report Third Quarter Financial Results on November 14, 2023 | MOUNTAIN VIEW, Calif. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2023 |
|
|
08/29/23
|
Summary ToggleIridex Announces Strategic Review to Unlock Shareholder Value | MOUNTAIN VIEW, Calif. , Aug. 29, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) announced today that its Board of Directors is undertaking, in consultation with its financial and legal advisors, a review and evaluation of strategic alternatives that may be available to the Company to |
|
|
08/10/23
|
Summary ToggleIridex Reports Second Quarter 2023 Financial Results | MOUNTAIN VIEW, Calif. , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 1, 2023 . |
|
|
07/27/23
|
Summary ToggleIridex to Report Second Quarter Financial Results on August 10, 2023 | MOUNTAIN VIEW, Calif. , July 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2023 |
|
|
05/11/23
|
Summary ToggleIridex Reports First Quarter 2023 Financial Results | MOUNTAIN VIEW, Calif. , May 11, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 1, 2023 . |
|
|
04/27/23
|
Summary ToggleIridex to Report First Quarter Financial Results on May 11, 2023 | MOUNTAIN VIEW, Calif. , April 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of 2023 |
|
|
03/09/23
|
Summary ToggleIridex Reports Fourth Quarter and Full Year 2022 Financial Results | Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth MOUNTAIN VIEW, Calif. , March 09, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today |
|
|
03/07/23
|
Summary ToggleIridex to Present at the 35th Annual Roth Conference | MOUNTAIN VIEW, Calif. , March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming 35 th Annual Roth Conference in |
|
|
03/02/23
|
Summary ToggleIridex Introduces New Research and Showcases Five Events at the AGS Meeting | Five Events at Booth #5 Discover the latest surgical techniques and outcomes published by the International MicroPulse TLT Consensus Panel . Watch Dr. Syril Dorairaj’s e-poster on prospective MicroPulse TLT dosimetry research outcomes. Demo Sweep Management Software for MicroPulse TLT. |
|
|
02/23/23
|
Summary ToggleIridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023 | MOUNTAIN VIEW, Calif. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and |
|
|
01/10/23
|
Summary ToggleIridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022 | Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth MOUNTAIN VIEW, Calif. , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today |
|
